Abstract 1678P
Background
Breast cancer have a significant impact on the life of married couples. Partners are faced with many challenges such as the heavy treatments and the body changes associated with the disease.
Methods
We conducted a study including patients treated for breast cancer in Salah Azaiz Institute. The aim was to evaluate the impact of cancer on the couple's relationship. The patients agreed to answer a marital adjustment questionnaire (MAQ).
Results
The study included 53 patients with a mean age of 52.25 years, ranging from 34 to 72 years. At the time of the study, 83% (n=44) had been married for between 3 and 60 years, with a mean of 22.5 years and a standard deviation of 11.4. The age at marriage was 27.80±6.9 years, with extremes ranging from 15 to 50 years. Fifteen per cent of patients had no children, and the number of children ranged from 1 to 5, with an average of 2.2. The average age difference between the married women and their partners was 5.3 years, with extremes ranging from one year to 23 years. More than half of the population studied in couple had intimacy problems (n=34),. The mean marital agreement score was 81.65 [41-120]. Eight couples no longer engaged in activities together outside the home and 39.5% (n=21) of them very little. Twenty-nine patients (54.7%) said that they almost never showed affection to their partners. The study of sexual activity showed an abstinence rate of 35.8% (n=19) compared to versus 0% before cancer. A quarter of our population had less than two sexual encounters per month after the disease, compared with 20.8% (n=11) and only 10% had more than 4 intercourses per month compared with 50.9% (n=27), before treatment. Twenty patients (37.3%) frequently disagreed about the sexual relationship. Fifty-four per cent (n=29) of the patients interviewed stated that they had a sexual complaint at the time of the survey: Among them, 32% (n=17) had spoken to their partners about the subject. Twenty-two (n=12) of the patients said they could no longer confide in their partner.
Conclusions
Breast cancer requires adjustments in married life, but with mutual support and open communication, couples can overcome these challenges together.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1699P - Impact of Latino ethnicity on the gut microbiome and response to immune checkpoint inhibition (ICI) with CBM588 in patients (pts) with metastatic renal cell cancer (mRCC)
Presenter: Regina Barragan-Carrillo
Session: Poster session 11
1700P - Impact of sarcomatoid (S) and rhabdoid (R) components (comp.) on the efficacy of nivolumab (N) +/- ipilimumab (I) in the first-line (L1) treatment of metastatic clear cell renal cell carcinoma (mRCC) in the randomized phase II BIONIKK trial
Presenter: Yann-Alexandre Vano
Session: Poster session 11
1701P - NEOTAX: A phase II trial of neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus
Presenter: Liangyou Gu
Session: Poster session 11
1702P - Updated results of phase II study of cabozantinib (Cabo) with nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma with divergent histologies (RCCdh)
Presenter: Bradley McGregor
Session: Poster session 11
1703P - Updated overall survival in patients with prior checkpoint inhibitor (CPI) therapy in the phase III TIVO-3 study
Presenter: Miguel Zugman
Session: Poster session 11
1704P - Potential surrogate endpoints for overall survival (OS) in immunotherapy (IO)-treated metastatic renal cell carcinoma (mRCC): An International Metastatic Database Consortium (IMDC) study
Presenter: Renee Saliby
Session: Poster session 11
1705P - Association between baseline radiological tumor burden (BRTB) and outcomes in metastatic clear cell renal cell carcinoma (mccRCC) treated with first line (1L) immunotherapy (IO)-based regimens
Presenter: Rashad Nawfal
Session: Poster session 11
1707P - A plasma proteomic based algorithm is associated with prognosis in renal cell carcinoma
Presenter: Eddy Saad
Session: Poster session 11
1708P - The clinical value of tumor-informed minimal residual disease detection in renal cell carcinoma
Presenter: linhui wang
Session: Poster session 11